April is Parkinson’s Awareness Month, a time to give special attention to a disease that affects approximately 100,000 Canadians. As a centre for both research and clinical treatment of Parkinson’s disease (PD), the Montreal Neurological Institute and Hospital (The Neuro) offers many specialized services and opportunities to participate in research to PD patients.
Stuart Trenholm, who joined The Neuro in 2017 as an assistant professor, has received a Career Development Award from The International Human Frontier Science Program Organization (HFSPO), the only Canadian researcher to receive one this year.
The Human Frontier Science Program is an international program of research support implemented by the HFSPO based in Strasbourg, France. Its aims are to promote intercontinental collaboration and training in cutting-edge, interdisciplinary research focused on the life sciences.
The institute that developed the “Montreal Procedure” continues to be on the cutting edge
The Neuro is recognized worldwide as a leader in epilepsy research and treatment. From the beginning, Neuro founder, Dr. Wilder Penfield, made epilepsy a central focus. He and his colleagues developed a surgical treatment for epilepsy patients known as the “Montreal Procedure,” which today is in use throughout the world. The Neuro became a pioneer in studying epilepsy through the use of electroencephalography (EEG) and magnetic resonance imaging (MRI).
2017 Québec Science Discovery of the Year Award goes to the cancer-detection probe developed by Kevin Petrecca and Frédéric Leblond
Québec Science magazine’s 25-year tradition continues: every fall, a jury comprised of researchers and journalists selects the top 10 most impressive discoveries in Quebec in the past year and the public is asked to vote to select the winner. This year, a cancer-detection probe was chosen by nearly a third of approximately 4,400 votes cast in the 2017 Discovery of the Year contest.
Women scientists and clinicians are creators and changemakers, expanding the boundaries of human knowledge
The Neuro has launched Neuro XXceptional - an exciting new year-long video series featuring women who tell us what drove them to become scientists and clinicians, and what they love about their work. At The Neuro, these exceptional professionals are improving the lives of patients, helping us understand how the brain works and how to treat neurological disease.
Industry and academia to share expertise in effort to develop improved methods to produce and characterize antibodies and reagents for neurological research
You’re about to turn 60, and you’re fretting. Your mother has had Alzheimer’s disease since the age of 65. At what age will the disease strike you? A Canadian study published in JAMA Neurology shows that the closer a person gets to the age at which their parent exhibited the first signs of Alzheimer’s, the more likely they are to have amyloid plaques, the cause of the cognitive decline associated with the disease, in their brain.
Canadian Open Neuroscience Platform will make disseminating and publishing data easier
Modern neuroscience research can produce massive amounts of data, which researchers can use to find patterns revealing anything from the first physiological signs of Alzheimer’s disease to a new drug target that could stop neurodegeneration. However, this data must be stored, processed, and distributed effectively.
Volume in brain region linked to physiological changes characteristic of AD
New research has drawn a link between changes in the brain’s anatomy and biomarkers that are known to appear at the earliest stages of Alzheimer’s disease (AD), findings that could one day provide a sensitive but non-invasive test for AD before cognitive symptoms appear.
NeuroSGC created to increase volume and quality of cell assays for drug discovery
A new partnership between the Structural Genomics Consortium (SGC) and the Montreal Neurological Institute and Hospital (The Neuro) will use a unique open science framework to help scientists discover new targets for drug development for neurological diseases.
The partnership, called NeuroSGC, will initially focus on Parkinson’s disease and amyotrophic lateral sclerosis (ALS), two of the most common neurodegenerative diseases.
Industry and academia team up for the benefit of people suffering from ALS
A unique industry-academia partnership will increase the rate at which promising drug compounds can be tested as potential treatments for amyotrophic lateral sclerosis (ALS), a disease with no known cure that affects 200,000 people worldwide.
The partnership between The Montreal Neurological Institute and Hospital (MNI) and Takeda Pharmaceutical Company Limited (Takeda) will allow compounds developed by Takeda scientists to be tested on cell lines produced at the MNI.
Senate of Canada recognizes outstanding contributions to the community
The Senate of Canada has awarded Alan Evans a Canada 150 medal for his commitment to advancements in Alzheimer’s disease and palliative care research. He was nominated by Senator Judith Seidman, a former research fellow at the Montreal Neurological Institute and Hospital, and Associate Professor of the McGill School of Social Work.
Grants for Heather Durham, Stefano Stifani and Jay Ross total just over $2 million
Three MNI researchers have received grants from the ALS Society of Canada worth a total of more than $2 million.
Brain stimulation can change how much we enjoy and value music
Enjoyment of music is considered a subjective experience; what one person finds gratifying, another may find irritating. Music theorists have long emphasized that although musical taste is relative, our enjoyment of music, be it classical or heavy metal, arises, among other aspects, from structural features of music, such as chord or rhythm patterns that generate anticipation and expectancy.
The Azrieli Centre for Autism Research will foster innovations in therapy and a better understanding of Autism Spectrum Disorder.
A new research centre in Montreal will help lift the shroud of mystery surrounding autism spectrum disorder (ASD), and lead to the development of better diagnostic tools and more effective therapies for people with autism.